Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.
We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C-peptide, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-2, and endometrial cancer risk. Among...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Journal article |
| שפה: | English |
| יצא לאור: |
2007
|
| _version_ | 1826304569934610432 |
|---|---|
| author | Cust, A Allen, N Rinaldi, S Dossus, L Friedenreich, C Olsen, A Tjønneland, A Overvad, K Clavel-Chapelon, F Boutron-Ruault, M Linseisen, J Chang-Claude, J Boeing, H Schulz, M Benetou, V Trichopoulou, A Trichopoulos, D Palli, D Berrino, F Tumino, R Mattiello, A Vineis, P Quirós, JR Agudo, A Sánchez, M |
| author_facet | Cust, A Allen, N Rinaldi, S Dossus, L Friedenreich, C Olsen, A Tjønneland, A Overvad, K Clavel-Chapelon, F Boutron-Ruault, M Linseisen, J Chang-Claude, J Boeing, H Schulz, M Benetou, V Trichopoulou, A Trichopoulos, D Palli, D Berrino, F Tumino, R Mattiello, A Vineis, P Quirós, JR Agudo, A Sánchez, M |
| author_sort | Cust, A |
| collection | OXFORD |
| description | We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C-peptide, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-2, and endometrial cancer risk. Among pre- and post-menopausal women, who were not currently using exogenous hormones, 286 women developed incident endometrial cancer during an average 5.1 years follow-up. Using risk set sampling, 555 matched control subjects were selected. In conditional logistic regression models adjusted for matching factors only, endometrial cancer risk increased with increasing serum levels of C-peptide (relative risks (RR) for the top vs. bottom quartile = 2.13 [95% confidence interval (CI) 1.33-3.41], p(trend) = 0.001, and decreasing serum levels of IGFBP-2 (RR for the top vs. bottom quartile = 0.56 [95% CI 0.35-0.90], p(trend) = 0.03, but was not significantly associated with IGFBP-1 levels (RR for the top vs. bottom quartile = 0.76 [95% CI 0.47-1.21], p(trend) = 0.25). In BMI-adjusted models, only the C-peptide association remained marginally statistically significant (RR for the top vs. bottom quartile = 1.56 [95% CI 0.94-2.57], p(trend) = 0.05 for C-peptide; 0.84 [95% CI 0.50-1.40], p(trend) = 0.74 for IGFBP-2; and 1.08 [95% CI 0.65-1.78], p(trend) = 0.86 for IGFBP-1 levels). These associations were stronger among nonfasting women (< or =< or =6 hr since last meal; 63% of subjects) but were not evident among fasting women, although the interactions were not statistically significant. The C-peptide-risk association was substantially attenuated after adjustment for free estradiol in postmenopausal women (RR for the top vs. bottom quartile = 1.28 [95% CI 0.67-2.45], p(trend) = 0.42. Our results provide modest support to the hypothesis that hyperinsulinaemia is a risk factor for endometrial cancer. |
| first_indexed | 2024-03-07T06:19:49Z |
| format | Journal article |
| id | oxford-uuid:f25a4272-6e3f-4eec-b169-f10bdb9d13c3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:19:49Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:f25a4272-6e3f-4eec-b169-f10bdb9d13c32022-03-27T12:03:13ZSerum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f25a4272-6e3f-4eec-b169-f10bdb9d13c3EnglishSymplectic Elements at Oxford2007Cust, AAllen, NRinaldi, SDossus, LFriedenreich, COlsen, ATjønneland, AOvervad, KClavel-Chapelon, FBoutron-Ruault, MLinseisen, JChang-Claude, JBoeing, HSchulz, MBenetou, VTrichopoulou, ATrichopoulos, DPalli, DBerrino, FTumino, RMattiello, AVineis, PQuirós, JRAgudo, ASánchez, MWe conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C-peptide, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-2, and endometrial cancer risk. Among pre- and post-menopausal women, who were not currently using exogenous hormones, 286 women developed incident endometrial cancer during an average 5.1 years follow-up. Using risk set sampling, 555 matched control subjects were selected. In conditional logistic regression models adjusted for matching factors only, endometrial cancer risk increased with increasing serum levels of C-peptide (relative risks (RR) for the top vs. bottom quartile = 2.13 [95% confidence interval (CI) 1.33-3.41], p(trend) = 0.001, and decreasing serum levels of IGFBP-2 (RR for the top vs. bottom quartile = 0.56 [95% CI 0.35-0.90], p(trend) = 0.03, but was not significantly associated with IGFBP-1 levels (RR for the top vs. bottom quartile = 0.76 [95% CI 0.47-1.21], p(trend) = 0.25). In BMI-adjusted models, only the C-peptide association remained marginally statistically significant (RR for the top vs. bottom quartile = 1.56 [95% CI 0.94-2.57], p(trend) = 0.05 for C-peptide; 0.84 [95% CI 0.50-1.40], p(trend) = 0.74 for IGFBP-2; and 1.08 [95% CI 0.65-1.78], p(trend) = 0.86 for IGFBP-1 levels). These associations were stronger among nonfasting women (< or =< or =6 hr since last meal; 63% of subjects) but were not evident among fasting women, although the interactions were not statistically significant. The C-peptide-risk association was substantially attenuated after adjustment for free estradiol in postmenopausal women (RR for the top vs. bottom quartile = 1.28 [95% CI 0.67-2.45], p(trend) = 0.42. Our results provide modest support to the hypothesis that hyperinsulinaemia is a risk factor for endometrial cancer. |
| spellingShingle | Cust, A Allen, N Rinaldi, S Dossus, L Friedenreich, C Olsen, A Tjønneland, A Overvad, K Clavel-Chapelon, F Boutron-Ruault, M Linseisen, J Chang-Claude, J Boeing, H Schulz, M Benetou, V Trichopoulou, A Trichopoulos, D Palli, D Berrino, F Tumino, R Mattiello, A Vineis, P Quirós, JR Agudo, A Sánchez, M Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title | Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title_full | Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title_fullStr | Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title_full_unstemmed | Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title_short | Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. |
| title_sort | serum levels of c peptide igfbp 1 and igfbp 2 and endometrial cancer risk results from the european prospective investigation into cancer and nutrition |
| work_keys_str_mv | AT custa serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT allenn serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT rinaldis serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT dossusl serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT friedenreichc serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT olsena serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT tjønnelanda serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT overvadk serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT clavelchapelonf serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT boutronruaultm serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT linseisenj serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT changclaudej serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT boeingh serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT schulzm serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT benetouv serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT trichopouloua serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT trichopoulosd serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT pallid serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT berrinof serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT tuminor serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT mattielloa serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT vineisp serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT quirosjr serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT agudoa serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition AT sanchezm serumlevelsofcpeptideigfbp1andigfbp2andendometrialcancerriskresultsfromtheeuropeanprospectiveinvestigationintocancerandnutrition |